Stay Updated with the Latest T. Rowe Price Active Crypto ETF TKNZ News in Real Time
Find TKNZ news now at Meyka AI. Stay informed with the latest T. Rowe Price Active Crypto ETF stocks updates, including price news, market analysis, and expert insights.
Quant USD Jumps 14.6% to $264.35 as RSI Hits Extreme Overbought 96
QNTUSD surged 14.6% in 24 hours to $264.35 with RSI at 96 and volume 21x average, signaling extreme overbought conditions.
Hedera USD Drops 15% to $0.1036 as RSI Cools From Overbought
HBARUSD fell 15% in 24 hours to $0.1036 on September 29, 2026, with RSI at 64.12 and volume 8.5x average.
Aave USD Surges 11.3% to $166.18 as RSI Hits Overbought 71.7
Aave USD jumped 11.3% to $166.18 in 24 hours with RSI at 71.7 and volume 3.2x average, signaling overbought conditions.
Zcash USD Falls 5.4% to $1403.15 as RSI Cools From Overbought
ZECUSD dropped $80.22 in 24 hours to $1403.15. RSI at 63.58 signals cooling momentum after recent strength.
Swiss GDP Growth Forecast Jumps to 1.7% for 2026 on Pharma Surge
Switzerland raises 2026 GDP forecast to 1.7% from 0.9% after Q2 growth hits 1.5%, strongest since 2021. Pharma drives half the gains, but inflation expected to rise.
Chainlink USD Falls 5.3% to $14.63 as RSI Hits Overbought 73
LINKUSD dropped 5.3% in 24 hours to $14.63 on September 29, 2026, despite RSI at 73 signaling overbought conditions and strong trend strength.
RBA Hikes Cash Rate to 4.60% on September 29, Highest Since 2011
RBA raises cash rate to 4.60%, the highest in 15 years. Fourth hike of 2026 adds $100 monthly to $700k mortgages. Markets price 60% chance of sixth hike by mid-2027.
Kelvin Wave Could Raise California Sea Levels Up to a Foot This Fall
A Kelvin wave traveling from the Pacific could raise California sea levels by up to a foot as El Niño develops. The wave is expected to reach San Diego in early to mid-October.
FDA Recalls 13,567 Bottles of Chlorthalidone After Dissolution Test Failure
FDA classifies chlorthalidone recall as Class II after 13,567 bottles fail dissolution testing. Inventia Healthcare’s second recall in three months raises quality concerns for blood pressure patients.